AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jun 4, 2021
31637_dirs_2021-06-03_7cef1007-1a21-4e0a-9faa-8371736a5784.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-01
Reporting Person: Schenkein David P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-01 | Common Stock | M | 3253 | $0.00 | Acquired | 3253 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-01 | Restricted Stock Units | $ | M | 3253 | Disposed | Common Stock (3253) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 26232 | Indirect |
| Common Stock | 31232 | Indirect |
Footnotes
F1: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
F2: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F4: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.